Oruka Therapeutics’ (ORKA) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Tuesday,RTT News reports. Wedbush currently has a $40.00 target price on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

ORKA has been the subject of several other reports. TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Thursday, October 31st. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $20.50 on Tuesday. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88. The stock has a market cap of $24.81 million, a PE ratio of -3.55 and a beta of 0.87. The firm’s 50 day simple moving average is $26.36.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $114,763,000. RTW Investments LP bought a new position in Oruka Therapeutics during the 3rd quarter valued at $45,359,000. Braidwell LP acquired a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $12,640,000. Great Point Partners LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth $12,614,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at $11,822,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.